These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

860 related articles for article (PubMed ID: 31891652)

  • 21. Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy.
    Wahl SGF; Dai HY; Emdal EF; Ottestad AL; Dale VG; Richardsen E; Halvorsen TO; Grønberg BH
    J Pathol Clin Res; 2021 May; 7(3):209-219. PubMed ID: 33502820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer.
    Hamfjord J; Guren TK; Glimelius B; Sorbye H; Pfeiffer P; Dajani O; Lingjaerde OC; Tveit KM; Pallisgaard N; Spindler KG; Kure EH
    Int J Cancer; 2021 Sep; 149(6):1385-1397. PubMed ID: 33961700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review.
    Abdallah R; Taly V; Zhao S; Pietrasz D; Bachet JB; Basile D; Mas L; Zaanan A; Laurent-Puig P; Taieb J
    Cancer Treat Rev; 2020 Jul; 87():102028. PubMed ID: 32485509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.
    Hussung S; Akhoundova D; Hipp J; Follo M; Klar RFU; Philipp U; Scherer F; von Bubnoff N; Duyster J; Boerries M; Wittel U; Fritsch RM
    BMC Cancer; 2021 Jan; 21(1):49. PubMed ID: 33430810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence.
    Amintas S; Fernandez B; Chauvet A; Chiche L; Laurent C; Belleannée G; Marty M; Buscail E; Dabernat S
    Sci Rep; 2022 Feb; 12(1):2976. PubMed ID: 35194118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
    Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
    Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients.
    Guo S; Shi X; Shen J; Gao S; Wang H; Shen S; Pan Y; Li B; Xu X; Shao Z; Jin G
    Br J Cancer; 2020 Mar; 122(6):857-867. PubMed ID: 31969677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma.
    Affolter KE; Hellwig S; Nix DA; Bronner MP; Thomas A; Fuertes CL; Hamil CL; Garrido-Laguna I; Scaife CL; Mulvihill SJ; Underhill HR
    Neoplasia; 2021 Sep; 23(9):859-869. PubMed ID: 34298235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.
    Yin L; Pu N; Thompson E; Miao Y; Wolfgang C; Yu J
    Clin Cancer Res; 2021 Feb; 27(3):740-748. PubMed ID: 33082211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing.
    Holm M; Andersson E; Osterlund E; Ovissi A; Soveri LM; Anttonen AK; Kytölä S; Aittomäki K; Osterlund P; Ristimäki A
    PLoS One; 2020; 15(11):e0239819. PubMed ID: 33237900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.
    Sclafani F; Chau I; Cunningham D; Hahne JC; Vlachogiannis G; Eltahir Z; Lampis A; Braconi C; Kalaitzaki E; De Castro DG; Wotherspoon A; Capdevila J; Glimelius B; Tarazona N; Begum R; Lote H; Hulkki Wilson S; Mentrasti G; Brown G; Tait D; Oates J; Valeri N
    Sci Rep; 2018 Jan; 8(1):1445. PubMed ID: 29362371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of the preoperative circulating tumor DNA
    Li S; Zhang G; Li X; Li X; Chen X; Xu Y; Ren H
    Pharmacogenomics; 2021 Jul; 22(11):657-667. PubMed ID: 34120460
    [No Abstract]   [Full Text] [Related]  

  • 34. Circulating tumour-derived KRAS mutations in pancreatic cancer cases are predominantly carried by very short fragments of cell-free DNA.
    Zvereva M; Roberti G; Durand G; Voegele C; Nguyen MD; Delhomme TM; Chopard P; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Brennan P; Foll M; Byrnes GB; McKay JD; Scelo G; Le Calvez-Kelm F
    EBioMedicine; 2020 May; 55():102462. PubMed ID: 32249202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of Recurrence With KRAS Mutational Burden Using Ultrasensitive Digital Polymerase Chain Reaction of Radial Resection Margin of Resected Pancreatic Ductal Adenocarcinoma.
    Kim SJ; Kim MJ; Han JS; Sung YN; An S; Lee JH; Song KB; Hwang DW; Lee SS; Cho H; Kim SC; Eshleman JR; Hong SM
    Pancreas; 2019 Mar; 48(3):400-411. PubMed ID: 30747828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.
    Kruger S; Heinemann V; Ross C; Diehl F; Nagel D; Ormanns S; Liebmann S; Prinz-Bravin I; Westphalen CB; Haas M; Jung A; Kirchner T; von Bergwelt-Baildon M; Boeck S; Holdenrieder S
    Ann Oncol; 2018 Dec; 29(12):2348-2355. PubMed ID: 30346475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer.
    Buscail L; Bournet B; Cordelier P
    Nat Rev Gastroenterol Hepatol; 2020 Mar; 17(3):153-168. PubMed ID: 32005945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.
    Brychta N; Krahn T; von Ahsen O
    Clin Chem; 2016 Nov; 62(11):1482-1491. PubMed ID: 27591291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage.
    Kirchweger P; Kupferthaler A; Burghofer J; Webersinke G; Jukic E; Schwendinger S; Weitzendorfer M; Petzer A; Függer R; Rumpold H; Wundsam H
    Eur J Surg Oncol; 2022 May; 48(5):1046-1053. PubMed ID: 34876329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.